<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=2023070 81第14047章Chrome&amp;ff =20231102141013<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231102141013" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 2 日星期四 18:10:15 +0000</lastbuilddate><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> 2023年世界心脏联合会风湿性心脏病超声心动图诊断指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>风湿性心脏病 (RHD) 是导致低收入和中等收入国家儿童和年轻人以及高收入国家某些高危人群发病和死亡的重要且可预防的原因。2012 年世界心脏联盟超声心动图标准为识别 RHD 提供了标准化方法，并促进了早期病例检测的改进。2012 年标准用于定义众多... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 2 日。doi：10.1038/s41569-023-00940-9。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">风湿性心脏病 (RHD) 是导致低收入和中等收入国家儿童和年轻人以及高收入国家某些高危人群发病和死亡的重要且可预防的原因。2012 年世界心脏联盟超声心动图标准为 RHD 的识别提供了标准化方法，并促进了早期病例检测的改进。2012 年的标准用于定义众多流行病学研究中的疾病负担，但研究人员和先驱者此后强调了其局限性，并促使其进行修订。在该指南的更新版本中，我们纳入了范围界定审查、专家小组和最终用户反馈中的证据，并提出了一种主动发现 RHD 病例的方法，包括使用筛选和确认标准。这些指南还引入了新的方法基于阶段的 RHD 分类，以确定疾病进展的风险。它们描述了基于人群的超声心动图主动病例发现和风险分层的最新证据和建议。还讨论了 RHD 主动病例发现的二级抗生素预防、超声心动图设备和任务共享世界心脏联合会 2023 为 RHD 流行地区的临床和研究应用提供了简明且更新的资源指南。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914787</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00940-9>10.1038/s41569-023-00940-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914787</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>乔斯林·鲁韦贝贝拉</dc:creator><dc:creator>詹姆斯·马兰古</dc:creator><dc:creator>朱利叶斯·查查·姆维塔</dc:creator><dc:creator>安娜·奥尔加·莫昆比</dc:creator><dc:creator>克莱奥尼斯·莫塔</dc:creator><dc:creator>艾美·奥凯洛</dc:creator><dc:creator>布鲁诺·纳西门托</dc:creator><dc:creator>琳·索鲁普</dc:creator><dc:creator>安德里亚·比顿</dc:creator><dc:creator>约瑟夫·卡多</dc:creator><dc:creator>亚历山大·凯斯纳</dc:creator><dc:creator>拉曼·克里希纳·库马尔</dc:creator><dc:creator>约翰·劳伦森</dc:creator><dc:creator>埃洛伊·马里琼</dc:creator><dc:creator>玛丽安娜·米拉贝尔</dc:creator><dc:creator>玛丽亚·卡尔莫·佩雷拉·努内斯</dc:creator><dc:creator>丹尼尔·皮内罗</dc:creator><dc:creator>福斯托·平托</dc:creator><dc:creator>凯特·罗尔斯顿</dc:creator><dc:creator>克雷格·塞布尔</dc:creator><dc:creator>艾米桑亚胡姆比</dc:creator><dc:creator>安妮塔·萨克塞纳</dc:creator><dc:creator>凯伦·斯利瓦</dc:creator><dc:creator>安德鲁·斯蒂尔</dc:creator><dc:creator>萨图派提亚·维亚利</dc:creator><dc:creator>加文·惠顿</dc:creator><dc:creator>奈杰尔·威尔逊</dc:creator><dc:creator>莉丝尔·祖尔克</dc:creator><dc:creator>博·雷梅尼</dc:creator><dc:date>2023-11-02</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>2023年世界心脏联合会风湿性心脏病超声心动图诊断指南</dc:title><dc:identifier>下午：37914787</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00940-9</dc:identifier></item><item><title>回复：针对心房颤动的症状关注：一种有前途的治疗方法和未来研究的途径</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e183-e184.doi:10.1016/j.jacc.2023.08.047。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914521</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.047>10.1016/j.jacc.2023.08.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914521</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>约瑟夫·萨恩霍尔姆</dc:creator><dc:creator>布扬·洛松</dc:creator><dc:creator>弗里德·布伦瑞克</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>回复：针对心房颤动的症状关注：一种有前途的治疗方法和未来研究的途径</dc:title><dc:identifier>下午:37914521</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.047</dc:identifier></item><item><title>关于 iCBT 对有症状的阵发性心房颤动患者的疗效需谨慎</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e181.doi:10.1016/j.jacc.2023.07.035。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914520</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.035>10.1016/j.jacc.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914520</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>彼得·安德森</dc:creator><dc:creator>詹姆斯·科因</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>关于 iCBT 对有症状的阵发性心房颤动患者的疗效需谨慎</dc:title><dc:identifier>下午：37914520</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.035</dc:identifier></item><item><title>患有心房颤动和心理健康症状的绝经后妇女：值得关注的群体</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e179.doi:10.1016/j.jacc.2023.07.037。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914519</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.037>10.1016/j.jacc.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914519</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>王洁仪</dc:creator><dc:creator>贾瑞婷</dc:creator><dc:creator>榆林路</dc:creator><dc:creator>于武敏</dc:creator><dc:creator>朱爱松</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>患有心房颤动和心理健康症状的绝经后妇女：值得关注的群体</dc:title><dc:identifier>下午：37914519</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.037</dc:identifier></item><item><title>超越表面：审视 iCBT 治疗心房颤动研究中的方法学偏差</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e177.doi:10.1016/j.jacc.2023.07.036。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914518</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.036>10.1016/j.jacc.2023.07.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914518</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿德里安·E·德赛·博斯特罗姆</dc:creator><dc:creator>约翰·伦德伯格</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>超越表面：审视 iCBT 治疗心房颤动研究中的方法学偏差</dc:title><dc:identifier>下午：37914518</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.036</dc:identifier></item><item><title>心肌肌钙蛋白测定可区分急性和慢性心肌损伤</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1885-1887.doi:10.1016/j.jacc.2023.08.048。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914517</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.048>10.1016/j.jacc.2023.08.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914517</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>尼尔斯·索伦森</dc:creator><dc:creator>郭琳琳</dc:creator><dc:creator>保罗·M·哈勒</dc:creator><dc:creator>法纳兹·德科迪</dc:creator><dc:creator>乔纳斯·莱马赫</dc:creator><dc:creator>阿琳娜·肖克</dc:creator><dc:creator>贝图尔·托普拉克</dc:creator><dc:creator>塔尼娅·泽勒</dc:creator><dc:creator>拉斐尔·特维伦博尔德</dc:creator><dc:creator>约翰内斯·T·诺伊曼</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心肌肌钙蛋白测定可区分急性和慢性心肌损伤</dc:title><dc:identifier>下午：37914517</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.048</dc:identifier></item><item><title> SGLT2i 与心力衰竭肾功能恶化：“高肌酐血症”耐受性的另一个证明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1864-1867.doi:10.1016/j.jacc.2023.09.797。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914516</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.797>10.1016/j.jacc.2023.09.797</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914516</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>史蒂文·G·科卡</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>SGLT2i 与心力衰竭肾功能恶化：“高肌酐血症”耐受性的另一个证明</dc:title><dc:identifier>下午：37914516</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.797</dc:identifier></item><item><title>索格列净的疗效与糖化血红蛋白水平无关</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1852-1853.doi:10.1016/j.jacc.2023.09.004。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914515</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.004>10.1016/j.jacc.2023.09.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914515</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>礼萨·莫赫比</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>索格列净的疗效与糖化血红蛋白水平无关</dc:title><dc:identifier>下午：37914515</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.004</dc:identifier></item><item><title> Sotagliflozin 对成人 2 型糖尿病患者的疗效与基线血红蛋白 A1c 的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论：在患有 HF 或肾脏疾病的 2 型糖尿病患者中，无论基线 HbA1c 如何，索格列净均可减少 HF 结局。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1842-1851.doi:10.1016/j.jacc.2023.08.050。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：SCORED（索格列净对有心血管风险的 2 型糖尿病和中度肾损伤患者心血管和肾脏事件的影响）和 SOLOIST-WHF（索格列净对心力衰竭恶化后 2 型糖尿病患者心血管事件的影响） ）试验表明，sotagliflozin（一种 SGLT1 和 SGLT2 抑制剂）可改善患有心力衰竭 (HF) 或肾脏疾病的 2 型糖尿病患者的预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们评估了索格列净对不同基线糖化血红蛋白 (HbA1c) 水平的个体心力衰竭临床结果的疗效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们纳入了 SCORED 和 SOLOIST-WHF 的所有成年人。主要结局是心血管死亡、心力衰竭住院和心力衰竭紧急就诊的综合结果。与安慰剂相比，索格列净的疗效通过基线 HbA1c 使用竞争风险边际评估进行评估。比例风险模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们识别了 11,744 名成年人。HbA1c ≤7.5% 的个体在 sotagliflozin 组（每 100 人年 11.2 人）经历主要结局的发生率低于安慰剂组（每 100 人年 15.5 人）（HR：0.73； 95% CI：0.57-0.93）。同样，HbA1c 为 7.6% 至 9.0% 的个体中，sotagliflozin 组（每 100 人年 7.3 人）经历主要结局的发生率低于安慰剂组（每 100 人年 9.4 人） （HR：0.77；95% CI：0.63-0.96）。这些结果在 HbA1c >; 9.0% 的个体中也一致，sotagliflozin 组的主​​要结局发生率（7.8/100 人年）低于安慰剂组组（每 100 人年 11.6 例）（HR：0.65；95% CI：0.50-0.84）。sotagliflozin 的疗效与基线 HbA1c 水平一致（交互作用 P = 0.58）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在患有 HF 或肾脏疾病的 2 型糖尿病患者中，无论基线 HbA1c 如何，索格列净均可减少 HF 结局。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914514</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.050>10.1016/j.jacc.2023.08.050</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914514</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>拉胡尔·阿加瓦尔</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>迈克尔·萨雷克</dc:creator><dc:creator>克里斯托弗·P·坎农</dc:creator><dc:creator>达伦·K·麦奎尔</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>雷纳托·D·洛佩斯</dc:creator><dc:creator>迈克尔·J·戴维斯</dc:creator><dc:creator>菲利普·班克斯</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>菲利普·加布里埃尔·施泰格</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Sotagliflozin 对成人 2 型糖尿病患者的疗效与基线血红蛋白 A1c 的关系</dc:title><dc:identifier>下午：37914514</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.050</dc:identifier></item><item><title>稳定胸痛无创成像测试的比较准确性：重要吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1839-1841.doi:10.1016/j.jacc.2023.09.805。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914513</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.805>10.1016/j.jacc.2023.09.805</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914513</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>斯文·普莱因</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>稳定胸痛无创成像测试的比较准确性：重要吗？</dc:title><dc:identifier>下午：37914513</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.805</dc:identifier></item><item><title>负荷灌注心脏磁共振与 SPECT 成像检测冠状动脉疾病的比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论：与门控 SPECT 相比，使用 0.1 mmol/kg 体重钆布醇进行的血管扩张剂应激灌注 CMR 在诊断和排除显着 CAD 方面具有更高的诊断准确性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1828-1838.doi:10.1016/j.jacc.2023.08.046。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：GadaCAD2 是 2 项国际、多中心、前瞻性 3 期临床试验之一，这些试验导致美国食品和药物管理局批准钆布醇用于评估已知或疑似冠状动脉疾病 (CAD) 成人的心肌灌注和晚期钆增强 (LGE) ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：预先设定的次要目标是确定应力灌注心血管磁共振 (CMR) 在检测显着 CAD 和排除显着 CAD 方面是否不劣于单光子发射计算机断层扫描 (SPECT)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：患有已知或疑似 CAD 的参与者接受研究休息和应激灌注 CMR，与使用标准临床方案进行的门控 SPECT 进行比较。对于 CMR，腺苷或热加腺松用作血管扩张剂。钆布醇的总剂量为 0.1 mmol/kg 体重参考标准是通过定量冠状动脉造影 (QCA) 定义的 70% 狭窄。冠状动脉计算机断层扫描血管造影阴性可以排除 CAD。分析按每位患者进行。CMR、SPECT 和 QCA 评估由独立的中央核心实验室读者进行盲法评估到临床信息。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：参与者主要为男性（61.4% 为男性；平均年龄 58.9 ± 10.2 岁），并从美国 (75.0%)、澳大利亚 (14.7%)、新加坡 (5.7%) 和加拿大 (4.6%) 招募。显着 CAD 的发生率为 24.5%（n = 72 of 294）。应力灌注 CMR 在特异性 (P = 0.002)、受试者工作特征曲线下面积 (P &lt; 0.001) 和准确性 (P = 0.003) 方面优于门控 SPECT。 、阳性预测值 (P &lt; 0.001) 和阴性预测值 (P = 0.041)。CMR 对 70% QCA 狭窄的敏感性不劣于也不优于门控 SPECT。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与门控 SPECT 相比，使用 0.1 mmol/kg 体重钆布醇进行的血管扩张剂应激灌注 CMR 在诊断和排除显着 CAD 方面具有更高的诊断准确性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914512</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.046>10.1016/j.jacc.2023.08.046</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914512</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>安德鲁·E·新井</dc:creator><dc:creator>珍妮特·舒尔茨-门格</dc:creator><dc:creator>迪潘·J·沙阿</dc:creator><dc:creator>韩尉迟</dc:creator><dc:creator>W帕特里夏·班德蒂尼</dc:creator><dc:creator>阿伦·亚伯拉罕</dc:creator><dc:creator>帕梅拉·K·伍达德</dc:creator><dc:creator>约瑟夫·B·塞尔瓦纳亚加姆</dc:creator><dc:creator>克里斯蒂安·汉密尔顿-克雷格</dc:creator><dc:creator>谭如三</dc:creator><dc:creator>詹姆斯·卡尔</dc:creator><dc:creator>林内特·张</dc:creator><dc:creator>克里斯托弗·M·克莱默</dc:creator><dc:creator>伯恩德·J·温特斯佩格</dc:creator><dc:creator>穆克什·G·哈里辛哈尼</dc:creator><dc:creator>斯科特·D·弗拉姆</dc:creator><dc:creator>马蒂亚斯·G·弗里德里希</dc:creator><dc:creator>伊戈尔·克莱姆</dc:creator><dc:creator>苏巴·V·拉曼</dc:creator><dc:creator>丹尼尔·哈弗斯托克</dc:creator><dc:creator>刘哲宇</dc:creator><dc:creator>冈瑟·布吕根沃特</dc:creator><dc:creator>玛尔塔·桑蒂乌斯特</dc:creator><dc:creator>丹尼尔·伯曼</dc:creator><dc:creator>达德利·彭内尔</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>负荷灌注心脏磁共振与 SPECT 成像检测冠状动脉疾病的比较</dc:title><dc:identifier>下午：37914512</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.046</dc:identifier></item><item><title>肾去神经术的持续奥德赛</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1824-1827.doi:10.1016/j.jacc.2023.09.795。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914511</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.795>10.1016/j.jacc.2023.09.795</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914511</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>曼尼什·维纳亚克</dc:creator><dc:creator>杰弗里·W·奥林</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>肾去神经术的持续奥德赛</dc:title><dc:identifier>下午：37914511</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.795</dc:identifier></item><item><title>服用抗高血压药物的患者去肾神经术的安全性和有效性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论：主要分析中各组之间没有显着差异。然而，多个次要终点分析有利于 RDN 优于假手术对照。（SPYRAL HTN-ON MED 研究 [使用 Symplicity Spyral 多电极肾去神经系统进行肾去神经的全球临床研究在没有抗高血压药物的情况下高血压不受控制的患者中]；NCT02439775）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1809-1823.doi:10.1016/j.jacc.2023.08.045。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：去肾神经术（RDN）可以降低在没有抗高血压药物的情况下高血压未得到控制的患者的血压（BP）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：该试验评估了 RDN 在抗高血压药物存在下的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：SPYRAL HTN-ON MED 是一项前瞻性、随机、假对照、患者和评估者盲法试验，招募了来自全球 56 个临床中心的患者。为患者开了 1 至 3 种抗高血压药物。患者被随机分配至射频 RDN 或假对照。主要疗效终点是使用贝叶斯试验设计和分析，在 6 个月时组间平均 24 小时动态收缩压的基线调整变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：RDN 组（n = 206；-6.5 ± 10.7 mm Hg）和假手术对照组（n = 131；-4.5 ± 10.3 mm Hg）之间平均 24 小时动态收缩压从基线到 6 个月的治疗差异）为-1.9 mm Hg（95% CI：-4.4至0.5 mm Hg；P = 0.12）。主要疗效分析中组间无显着差异，后验概率为0.51（贝叶斯处理差异：-0.03） mm Hg [95% CI: -2.82 至 2.77 mm Hg])。然而，假手术对照组患者的药物强度发生了变化和增加。与 6 个月时假手术对照组相比，RDN 与诊室收缩压降低相关（调整后）治疗差异：-4.9 mm Hg；P = 0.0015）。夜间血压降低和获胜比分析也有利于 RDN。253 名接受评估的患者中发生了 1 起不良安全事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：主要分析中各组之间没有显着差异。然而，多个次要终点分析有利于 RDN 优于假手术对照。（SPYRAL HTN-ON MED 研究 [使用 Symplicity Spyral 多电极肾去神经系统进行肾去神经的全球临床研究在没有抗高血压药物的情况下高血压不受控制的患者中]；NCT02439775）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37914510</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.045>10.1016/j.jacc.2023.08.045</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914510</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>大卫·E·坎扎里</dc:creator><dc:creator>雷蒙德·R·汤森</dc:creator><dc:creator>加尾一臣</dc:creator><dc:creator>菲利克斯·马哈福德</dc:creator><dc:creator>迈克尔·韦伯</dc:creator><dc:creator>罗兰·E·施密德</dc:creator><dc:creator>斯图尔特·波科克</dc:creator><dc:creator>康斯坦丁诺斯·齐乌菲斯</dc:creator><dc:creator>迪米特里奥斯·康斯坦丁尼迪斯</dc:creator><dc:creator>詹姆斯·崔</dc:creator><dc:creator>卡拉·东</dc:creator><dc:creator>卢卡斯·兰黛</dc:creator><dc:creator>黛比·L·科恩</dc:creator><dc:creator>小林大成</dc:creator><dc:creator>阿克塞尔·施密德</dc:creator><dc:creator>大卫·P·李</dc:creator><dc:creator>马德良</dc:creator><dc:creator>约阿希姆·韦尔</dc:creator><dc:creator>托尔加·阿格迪尔利奥卢</dc:creator><dc:creator>马库斯·P·施莱奇</dc:creator><dc:creator>沙拉德·谢蒂</dc:creator><dc:creator>钱丹·M·德维雷迪</dc:creator><dc:creator>珍妮丝·李</dc:creator><dc:creator>青木二郎</dc:creator><dc:creator>安德鲁·SP·夏普</dc:creator><dc:creator>理查德·安德森</dc:creator><dc:creator>马丁·费伊</dc:creator><dc:creator>凡妮莎·德布鲁因</dc:creator><dc:creator>桑迪普·布拉尔</dc:creator><dc:creator>迈克尔·伯姆</dc:creator><dc:creator>SPYRAL HTN-ON MED 研究人员</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>服用抗高血压药物的患者去肾神经术的安全性和有效性</dc:title><dc:identifier>下午：37914510</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.045</dc:identifier></item><item><title>磁性软机器人在体外操纵细胞外基质</title><link/>https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>动态机械控制对细胞微环境的重要性早已得到人们的重视。在最近一期的《Device》杂志中，Raman 及其同事设计了一种巧妙但可推广的工具来实现这一目标，并说明了工程细胞外基质的磁刺激可诱导肌肉纤维按照程序排列发挥作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 24 日：S0092-8674(23)01127-3. doi: 10.1016/j.cell.2023.10.011. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">动态机械控制对细胞微环境的重要性早已得到人们的重视。在最近一期的《Device》杂志中，Raman 及其同事设计了一种巧妙但可推广的工具来实现这一目标，并说明了工程细胞外基质的磁刺激可诱导肌肉纤维按照程序排列发挥作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37913767</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.011>10.1016/j.cell.2023.10.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37913767</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿维纳瓦·罗伊</dc:creator><dc:creator>克劳迪娅·勒贝尔</dc:creator><dc:date>2023-11-01</dc:date><dc:source>细胞</dc:source><dc:title>磁性软机器人在体外操纵细胞外基质</dc:title><dc:identifier>下午：37913767</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.011</dc:identifier></item><item><title>教育程度与心血管疾病的终生风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论和相关性：较低的教育程度与成年期的终生心血管疾病风险相关；高等教育转化为健康长寿。教育政策举措可能与长期健康益处相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 1 日。doi：10.1001/jamacardio.2023.3990。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：教育是健康的社会决定因素。量化其与终生心血管疾病 (CVD) 风险的关系具有公共卫生重要性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：计算 CVD 事件和 CVD 亚型的终生风险估计，并通过教育估计有和没有 CVD 的生存年数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：包括以社区为基础的队列研究，其中使用了 1985 年至 2015 年 6 项前瞻性队列研究的个人数据汇总，并裁定了心血管事件。研究小组使用改良的 Kaplan-Meier 评估了教育与终生 CVD 风险之间的关联和 Cox 模型解释了非心血管死亡的竞争风险。研究小组通过欧文限制均值的教育以及在 CVD 风险评估中增加教育程度的效用估计了有和没有 CVD 的生存年数。参与者（基线 40 至 59 岁和 60 岁）年龄到 79 岁）基线时没有 CVD，并且有完整的教育、心血管危险因素和前瞻性 CVD 结果数据。数据分析时间为 2022 年 1 月至 2022 年 9 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：教育程度（高中以下、高中毕业、部分大学或大学毕业生）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：心血管事件（致命性和非致命性冠心病、心力衰竭和中风；CVD 相关死亡；以及包含任何这些事件的总 CVD）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 40 998 名参与者（23 305 名女性 [56.2%]），男性平均（SD）年龄为 58.1（9.7）岁，女性为 58.3（9.9）岁。中学或高中毕业的人终生 CVD 风险较高。在中年男性中，CVD 事件的竞争风险比 (HR) 为 1.58 (95% CI, 1.38-1.80)、1.30 (95% CI, 1.10-1.46)与完成大学学业的女性相比，高中以下学历、高中学历和大学学历的女性的 HR 分别为 1.16 (95% CI, 1.00-1.34)。在女性中，这些竞争 HR 为 1.70 (95% CI, 1.49) -1.95)、1.19 (95% CI, 1.05-1.35) 和 0.98 (95% CI, 0.83-1.15)。受过高等教育的个体在发生 CVD 之前的寿命较长。教育对增强 CVD 风险预测的贡献有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：较低的教育程度与成年期的终生心血管疾病风险相关；高等教育转化为健康长寿。教育政策举措可能与长期健康益处相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37910110</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3990>10.1001/jamacardio.2023.3990</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37910110</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>贾里德·W·马格纳尼</dc:creator><dc:creator>宁红艳</dc:creator><dc:creator>约翰·T·威尔金斯</dc:creator><dc:creator>唐纳德·M·劳埃德·琼斯</dc:creator><dc:creator>诺琳娜·B·艾伦</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>教育程度与心血管疾病的终生风险</dc:title><dc:identifier>下午：37910110</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3990</dc:identifier></item><item><title>心房颤动脉冲场消融后按性别划分的临床结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论和相关性：这项队列研究的结果表明，房颤 PFA 后，临床有效性或安全性事件不存在显着的性别差异。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 11 月 1 日。doi：10.1001/jamacardio.2023.3752。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：之前的研究使用射频或冷冻消融等传统热消融方式治疗房颤 (AF)，评估患者性别与临床结果的关系，但由于结果参差不齐，因此存在争议。脉冲场消融 (PFA) 是一种新型 AF 消融能量方式，已证明优先心肌组织消融具有独特的安全性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：比较脉冲场消融批准后临床使用的方法、功效和安全性多国调查 (MANIFEST-PF) 登记中接受 PFA 治疗 AF 的患者的性别差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、背景和参与者：这是一项 MANIFEST-PF 注册数据的回顾性队列研究，其中包括 2021 年 3 月至 2022 年 5 月期间接受监管批准后使用 PFA 治疗 AF 的连续患者，中位随访时间为 1 年。 -PF 是一项跨国、回顾性分析、前瞻性登记的患者级别登记，包括 24 个欧洲中心。该研究包括所有因阵发性或持续性 AF 首次接受 PFA 的连续登记患者（年龄≥18 岁）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：对 AF 患者进行 PFA。所有患者均接受肺静脉隔离和额外消融，由操作者酌情进行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要有效性结果是在 3 个月的空白期后 30 秒或更长时间内没有临床记录的房性心律失常。主要安全性结果是急性（术后 7 天）和慢性（>; 7 天）的综合结果。 ) 主要不良事件 (MAE)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 1568 名接受 PFA 的 AF 患者（平均 [SD] 年龄，64.5 [11.5] 岁；1015 名男性 [64.7%]）中，女性患者与男性患者相比，年龄较大（平均 [SD] 年龄，68 岁） [10] 岁 vs 62 [12] 岁；P &lt; .001），阵发性 AF 较多（70.2% [553 人中的 388 人] vs 62.4% [1015 人中的 633 人]；P = .002），但合并症较少，例如冠状动脉疾病（9% [553 人中的 38 人] vs 15.9% [1015 人中的 129 人]；P &lt; .001）、心力衰竭（10.5% [553 人中的 58 人] vs 16.6% [1015 人中的 168 人]；P = .001），以及睡眠呼吸暂停（4.7% [553 人中的 18 人] vs 11.7% [1015 人中的 84 人]；P &lt; .001）。99.8% 的女性（553 人中的 552 人）和 98.9% 的男性（1015 人中的 1004 人； P = .90) 患者。22.4% 的女性患者（553 例中的 124 例）和 23.1% 的男性患者（1015 例中的 235 例；P = .79）进行了额外消融。1 年 Kaplan-Meier 估计的房颤自由度男性和女性患者的心律失常相似（79.0%；95% CI，76.3%-81.5% vs 76.3%；95% CI，72.5%-79.8%；P = .28）。急性严重程度也没有显着差异。组间 AE（男性，1.5% [1015 人中的 16 人] vs 女性，2.5% [553 人中的 14人]；P = .19）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：这项队列研究的结果表明，房颤 PFA 后，临床有效性或安全性事件不存在显着的性别差异。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37910101</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3752>10.1001/jamacardio.2023.3752</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37910101</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>莫希特·K·图拉加姆</dc:creator><dc:creator>彼得·诺伊齐尔</dc:creator><dc:creator>鲍里斯·施密特</dc:creator><dc:creator>托拜厄斯·赖克林</dc:creator><dc:creator>卡尔斯·内文</dc:creator><dc:creator>安德烈亚斯·梅茨纳</dc:creator><dc:creator>吉姆·汉森</dc:creator><dc:creator>尤里·布劳</dc:creator><dc:creator>菲利普·莫里</dc:creator><dc:creator>托马斯·阿伦兹</dc:creator><dc:creator>菲利普·萨默</dc:creator><dc:creator>安特·安尼奇</dc:creator><dc:creator>弗雷德里克·安塞尔姆</dc:creator><dc:creator>塞尔吉·博韦达</dc:creator><dc:creator>汤姆·德内克</dc:creator><dc:creator>史蒂芬·威廉斯</dc:creator><dc:creator>佩皮因·范德沃特</dc:creator><dc:creator>罗兰·蒂尔兹</dc:creator><dc:creator>森利船佐子</dc:creator><dc:creator>丹尼尔·谢尔</dc:creator><dc:creator>礼萨·瓦基里</dc:creator><dc:creator>丹尼尔·史蒂文</dc:creator><dc:creator>约瑟夫·考茨纳</dc:creator><dc:creator>约翰·维根</dc:creator><dc:creator>皮埃尔·贾伊斯</dc:creator><dc:creator>扬·佩特鲁</dc:creator><dc:creator>朱利安·春</dc:creator><dc:creator>洛朗·罗滕</dc:creator><dc:creator>安娜·芙婷</dc:creator><dc:creator>马克·D·勒莫万</dc:creator><dc:creator>马丁·鲁瓦尔德</dc:creator><dc:creator>巴特·穆德</dc:creator><dc:creator>安妮·罗林</dc:creator><dc:creator>海科·莱尔曼</dc:creator><dc:creator>托马斯·芬克</dc:creator><dc:creator>兹林卡·尤里西克</dc:creator><dc:creator>科朗坦·肖蒙</dc:creator><dc:creator>拉奎尔·阿德里诺</dc:creator><dc:creator>卡琳·南特威奇</dc:creator><dc:creator>梅兰妮·古纳瓦德内</dc:creator><dc:creator>亚历山大·乌斯</dc:creator><dc:creator>克里斯蒂安-亨德里克·黑格尔</dc:creator><dc:creator>马丁·曼宁格</dc:creator><dc:creator>扬-埃里克·博宁</dc:creator><dc:creator>阿里安苏丹</dc:creator><dc:creator>彼特·佩克尔</dc:creator><dc:creator>彼得·库普曼</dc:creator><dc:creator>尼古拉斯·德瓦尔</dc:creator><dc:creator>托马斯·库弗</dc:creator><dc:creator>维韦克·Y·雷迪</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>心房颤动脉冲场消融后按性别划分的临床结果</dc:title><dc:identifier>下午：37910101</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3752</dc:identifier></item><item><title>脉冲场缩小心房颤动消融中的性别差距 - 令人振奋的见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37910095/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 1 日。doi：10.1001/jamacardio.2023.4009。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37910095/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37910095</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4009>10.1001/jamacardio.2023.4009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37910095</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>彼得·M·基斯特勒</dc:creator><dc:creator>路易丝·塞根</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>脉冲场缩小心房颤动消融中的性别差距 - 令人振奋的见解</dc:title><dc:identifier>下午：37910095</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4009</dc:identifier></item><item><title> 1999-2020 年美国成人低密度脂蛋白胆固醇升高的患病率、认知度和治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37910086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 11 月 1 日。doi：10.1001/jamacardio.2023.3931。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37910086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37910086</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3931>10.1001/jamacardio.2023.3931</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37910086</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>艾哈迈德·赛义德</dc:creator><dc:creator>安·玛丽·纳瓦尔</dc:creator><dc:creator>莱安德罗·斯利普祖克</dc:creator><dc:creator>克里斯蒂·M·巴兰坦</dc:creator><dc:creator>扎伊纳布·萨马德</dc:creator><dc:creator>卡尔·拉维</dc:creator><dc:creator>萨利姆·维拉尼</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>1999-2020 年美国成人低密度脂蛋白胆固醇升高的患病率、认知度和治疗</dc:title><dc:identifier>下午：37910086</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3931</dc:identifier></item><item><title>线粒体蛋白翻译减少促进心肌细胞增殖和心脏再生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37905452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231102141013&amp;v=2.17.9.post6+86293ac<description>结论：这些数据强调了 MRPS5/ATF4 在心肌细胞中的关键作用，以及治疗心肌损伤的疗法的令人兴奋的新研究途径。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 31 日。doi：10.1161/CIRCULATIONAHA.122.061192。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The importance of mitochondria in normal heart function are well recognized and recent studies have implicated changes in mitochondrial metabolism with some forms of heart disease. Previous studies demonstrated that knockdown of the mitochondrial ribosomal protein S5 (MRPS5) by small interfering RNA (siRNA) inhibits mitochondrial translation and thereby causes a mitonuclear protein imbalance. Therefore, we decided to examine the effects of MRPS5 loss and the role of these processes on cardiomyocyte proliferation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We deleted a single allele of MRPS5 in mice and used left anterior descending coronary artery ligation surgery to induce myocardial damage in these animals. We examined cardiomyocyte proliferation and cardiac regeneration both in vivo and in vitro. Doxycycline treatment was used to inhibit protein translation. Heart function in mice was assessed by echocardiography. Quantitative real-time polymerase chain reaction and RNA sequencing were used to assess changes in transcription and chromatin immunoprecipitation (ChIP) and BioChIP were used to assess chromatin effects. Protein levels were assessed by Western blotting and cell proliferation or death by histology and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. Adeno-associated virus was used to overexpress genes. The luciferase reporter assay was used to assess promoter activity. Mitochondrial oxygen consumption rate, ATP levels, and reactive oxygen species were also analyzed. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We determined that deletion of a single allele of MRPS5 in mice results in elevated cardiomyocyte proliferation and cardiac regeneration; this observation correlates with improved cardiac function after induction of myocardial infarction. We identified ATF4 (activating transcription factor 4) as a key regulator of the mitochondrial stress response in cardiomyocytes from Mrps5 <sup>+/-</sup> mice; furthermore, ATF4 (activating transcription factor 4) regulates Knl1 (kinetochore scaffold 1) leading to an increase in cytokinesis during cardiomyocyte proliferation. The increased cardiomyocyte proliferation observed in Mrps5+/- mice was attenuated when one allele of Atf4 was deleted genetically (Mrps5 <sup>+/-</sup> /Atf4 <sup>+/-</sup> ), resulting in the loss in the capacity for cardiac regeneration. Either MRPS5 inhibition (or as we also demonstrate, doxycycline treatment) activate a conserved regulatory mechanism that increases the proliferation of human induced pluripotent stem cell-derived cardiomyocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These data highlight a critical role for MRPS5/ATF4 in cardiomyocytes and an exciting new avenue of study for therapies to treat myocardial injury.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37905452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37905452</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061192>10.1161/CIRCULATIONAHA.122.061192</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37905452</guid><pubDate> Tue, 31 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Feng Gao</dc:creator><dc:creator> Tian Liang</dc:creator><dc:creator> Yao Wei Lu</dc:creator><dc:creator> Linbin Pu</dc:creator><dc:creator> Xuyang Fu</dc:creator><dc:creator> Xiaoxuan Dong</dc:creator><dc:creator> Tingting Hong</dc:creator><dc:creator> Feng Zhang</dc:creator><dc:creator> Ning Liu</dc:creator><dc:creator> Yuxia Zhou</dc:creator><dc:creator> Hongkun Wang</dc:creator><dc:creator> Ping Liang</dc:creator><dc:creator> Yuxuan Guo</dc:creator><dc:creator> Hong Yu</dc:creator><dc:creator> Wei Zhu</dc:creator><dc:creator> Xinyang Hu</dc:creator><dc:creator> Hong Chen</dc:creator><dc:creator> Bin Zhou</dc:creator><dc:creator> William T Pu</dc:creator><dc:creator> John D Mably</dc:creator><dc:creator> Jian&#39;an Wang</dc:creator><dc:creator> Da-Zhi Wang</dc:creator><dc:creator> Jinghai Chen</dc:creator><dc:date> 2023-10-31</dc:date><dc:source> Circulation</dc:source><dc:title> Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration</dc:title><dc:identifier> pmid:37905452</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.061192</dc:identifier></item><item><title> Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers</title><link/> https://pubmed.ncbi.nlm.nih.gov/37905415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231102141013&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Our findings indicate that CD177^(+) neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177^(+) neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 31. doi: 10.1161/CIRCULATIONAHA.123.064734. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) share similar clinical manifestations, including cardiovascular complications, suggesting similar underlying immunopathogenic processes. Aberrant neutrophil activation may play a crucial role in the shared pathologies of KD and MIS-C; however, the associated pathogenic mechanisms and molecular drivers remain unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We performed a single-cell meta-analysis of neutrophil activation with 103 pediatric single-cell transcriptomic peripheral blood mononuclear cell data across 9 cohorts, including healthy controls, KD, MIS-C, compared with dengue virus infection, juvenile idiopathic arthritis, and pediatric celiac disease. We used a series of computational analyses to investigate the shared neutrophil transcriptional programs of KD and MIS-C that are linked to systemic damage and cardiac pathologies, and suggested Food and Drug Administration-approved drugs to consider as KD and MIS-C treatment. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We meta-analyzed 521 950 high-quality cells. We found that blood signatures associated with risks of cardiovascular events are enriched in neutrophils of KD and MIS-C. We revealed the expansion of CD177 <sup>+</sup> neutrophils harboring hyperactivated effector functions in both KD and MIS-C, but not in healthy controls or in other viral-, inflammatory-, or immune-related pediatric diseases. KD and MIS-C CD177 <sup>+</sup> neutrophils had highly similar transcriptomes, marked by conserved signatures and pathways related to molecular damage. We found the induction of a shared neutrophil expression program, potentially regulated by SPI1 (Spi-1 proto-oncogene), which confers enhanced effector functions, especially neutrophil degranulation. CD177 and shared neutrophil expression program expressions were associated with acute stages and attenuated during KD intravenous immunoglobulin treatment and MIS-C recovery. Network analysis identified hub genes that correlated with the high activation of CD177 <sup>+</sup> neutrophils. Disease-gene association analysis revealed that the CD177 <sup>+</sup> neutrophil shared neutrophil expression program was associated with the development of coronary and myocardial disorders. Last, we identified and validated TSPO (translocator protein) and S100A12 (S100 calcium-binding protein A12) as main molecular targets, for which the Food and Drug Administration-approved drugs methotrexate, zaleplon, metronidazole, lorazepam, clonazepam, temazepam, and zolpidem, among others, are primary candidates for drug repurposing. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our findings indicate that CD177 <sup>+</sup> neutrophils may exert systemic pathological damage contributing to the shared morbidities in KD and MIS-C. We uncovered potential regulatory drivers of CD177 <sup>+</sup> neutrophil hyperactivation and pathogenicity that may be targeted as a single therapeutic strategy for either KD or MIS-C.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37905415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37905415</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064734>10.1161/CIRCULATIONAHA.123.064734</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37905415</guid><pubDate> Tue, 31 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Jan Vincent B Beltran</dc:creator><dc:creator> Fang-Ping Lin</dc:creator><dc:creator> Chaw-Liang Chang</dc:creator><dc:creator> Tai-Ming Ko</dc:creator><dc:date> 2023-10-31</dc:date><dc:source> Circulation</dc:source><dc:title> Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers</dc:title><dc:identifier> pmid:37905415</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064734</dc:identifier></item><item><title> ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37905403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231102141013&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 31. doi: 10.1161/CIRCULATIONAHA.123.066680. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Angina with nonobstructive coronary arteries is a common condition for which no effective treatment has been established. We hypothesized that the measurement of coronary flow reserve (CFR) allows identification of patients with angina with nonobstructive coronary arteries who would benefit from anti-ischemic therapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients with angina with nonobstructive coronary arteries underwent blinded invasive CFR measurement and were randomly assigned to receive 4 weeks of amlodipine or ranolazine. After a 1-week washout, they crossed over to the other drug for 4 weeks; final assessment was after the cessation of study medication for another 4 weeks. The primary outcome was change in treadmill exercise time, and the secondary outcome was change in Seattle Angina Questionnaire summary score in response to anti-ischemic therapy. Analysis was on a per protocol basis according to the following classification: coronary microvascular disease (CMD group) if CFR&lt;2.5 and reference group if CFR≥2.5. The study protocol was registered before the first patient was enrolled (International Standard Randomised Controlled Trial Number: ISRCTN94728379). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Eighty-seven patients (61±8 years of age; 62% women) underwent random assignment (57 CMD group and 30 reference group). Baseline exercise time and Seattle Angina Questionnaire summary scores were similar between groups. The CMD group had a greater increment (delta) in exercise time than the reference group in response to both amlodipine (difference in delta, 82 s [95% CI, 37-126 s]; <i>P</i> &lt;0.001) and ranolazine (difference in delta, 68 s [95% CI, 21-115 s]; <i>P</i> =0.005). The CMD group reported a greater increment (delta) in Seattle Angina Questionnaire summary score than the reference group in response to ranolazine (difference in delta, 7 points [95% CI, 0-15]; <i>P</i> =0.048), but not to amlodipine (difference in delta, 2 points [95% CI, -5 to 8]; <i>P</i> =0.549). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37905403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231102141013&v=2.17.9.post6+86293ac">37905403</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066680>10.1161/CIRCULATIONAHA.123.066680</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37905403</guid><pubDate> Tue, 31 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Aish Sinha</dc:creator><dc:creator> Haseeb Rahman</dc:creator><dc:creator> Abdel Douiri</dc:creator><dc:creator> Ozan M Demir</dc:creator><dc:creator> Kalpa De Silva</dc:creator><dc:creator> Brian Clapp</dc:creator><dc:creator> Ian Webb</dc:creator><dc:creator> Ankur Gulati</dc:creator><dc:creator> Pedro Pinho</dc:creator><dc:creator> Utkarsh Dutta</dc:creator><dc:creator> Howard Ellis</dc:creator><dc:creator> Ajay M Shah</dc:creator><dc:creator> Amedeo Chiribiri</dc:creator><dc:creator> Michael Marber</dc:creator><dc:creator> Andrew J Webb</dc:creator><dc:creator> Divaka Perera</dc:creator><dc:date> 2023-10-31</dc:date><dc:source> Circulation</dc:source><dc:title> ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial</dc:title><dc:identifier> pmid:37905403</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.066680</dc:identifier></item></channel></rss>